Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Humiome Post LB (DSM-Firmenich)
- Development stage
- Preclinical
- Lead developer
- DSM-Firmenich
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Humiome Post LB (also known as Humiome Postbiotics) is a postbiotic ingredient developed by DSM-Firmenich following its acquisition of Adare Biome. It is composed of two proprietary inactivated *Lactobacillus* strains (*L. fermentum* and *L. delbrueckii*), their metabolites, and the fermented culture medium, produced via a specialized ECHO fermentation process. As a postbiotic, it consists of inanimate microorganisms and their components that provide health benefits without the risks associated with live probiotics, such as translocation or antibiotic resistance. Humiome Post LB is primarily targeted at gut health, where it modulates the microbiome, supports gut barrier integrity, and improves bowel regularity. It is also being researched for broader applications in immune health, metabolic health, brain health, and healthy aging, supported by extensive clinical and scientific documentation.
- Brand names
- Humiome Post LBHumiome Postbiotics
- Other names
- Lactobacillus LBLactobacillus acidophilus LB
Beyond the preview
Go deeper on Humiome Post LB (DSM-Firmenich).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humiome Post LB (DSM-Firmenich).